

DATE: \_\_\_/\_\_\_/\_\_\_ TX # \_\_\_/\_\_\_ BODY WEIGHT IN LBS \_\_\_\_\_

CASE #: BODY WEIGHT IN KGS \_\_\_\_\_

CLIENT NAME:

PATIENT NAME:

M<sup>2</sup> (FROM CONVERSION CHART) \_\_\_\_\_

**MITOXANTRONE PROTOCOL**

(CAN BE SUBSTITUTED FOR DOXORUBICIN IN SPECIFIC INSTANCES)

**CANINE**

<b><u>Drug</u></b>	<b><u>Dosage</u></b>	<b><u>This animal's calculated dose</u></b>
<b>Mitoxantrone (2 mg/mL)</b>	5.0-6.0 mg/m <sup>2</sup> IV (5-10 minutes) q 3 weeks diluted to 50 mL total volume in saline	_____ mg

**FELINE**

<b><u>Drug</u></b>	<b><u>Dosage</u></b>	<b><u>This animal's calculated dose</u></b>
<b>Mitoxantrone (2 mg/mL)</b>	6.0-6.5 mg/m <sup>2</sup> IV (5-10 minutes) q 3 weeks diluted to 20 mL total volume in saline	_____ mg

For both species: Prior to each treatment and at 7-10 days post-treatment, a CBC should be performed. Please contact the oncology service about dosage adjustments if the neutrophil count is < 2500 or the platelet count is < 80,000. Broad-spectrum antibiotics should be administered if the neutrophil count is < 1500.

**PLEASE CONTACT THE ONCOLOGY SERVICE WITH ANY QUESTIONS AT**

**Department of Clinical Sciences**

**Auburn University AL 36849**

**phone: (334)-844-4690**

**fax: (334)-844-6034**

SMITH/ August 2001